No Data
No Data
Solid Earnings May Not Tell The Whole Story For Medicalsystem Biotechnology (SZSE:300439)
Meikang Biotech: 2024 Semi-Annual Report Summary
Meikang Biotech: 2024 Semi-Annual Report
Medicalsystem Biotechnology (300439.SZ) subsidiary terminates the cooperation on the Medical Linear Accelerator Radiotherapy Center project with Yinzhou Hospital.
Medicalsystem Biotechnology (300439.SZ) announced that its wholly-owned subsidiary Ningbo Medicalsystem Shengda Biotechnology Co., Ltd. (abbreviated as...
Medicalsystem biotechnology (300439.SZ): intends to sign the 'Termination Agreement on the Medical Linear Accelerator Radiotherapy Center Project' with Yinzhou Hospital.
On October 25, 2022, Medicalsystem Biotechnology (300439.SZ) announced that the fourth Board of Directors and the fourteenth Supervisory Board meeting were held. They respectively reviewed and approved the proposal for the cooperation agreement and related trade of the wholly-owned subsidiary. The agreement allows the wholly-owned subsidiary Ningbo Medicalsystem Shengda Biotechnology Co., Ltd. (referred to as 'Shengda Biotechnology') to collaborate with Ningbo Yinzhou Traditional Chinese Hospital (referred to as 'Yinzhou Traditional Chinese Hospital') to establish a medical linear accelerator radiotherapy center project. The collaboration aims to conduct tumor diagnosis, treatment, research, and clinical work. The associated transaction amount involved in this collaboration is [...].
Medicalsystem Biotechnology (300439.SZ) announced its performance for the first half of the year, with a net income of 0.178 billion yuan, an increase of 2.06%.
Medicalsystem Biotechnology (300439.SZ) released its 2024 interim report, with revenue of 0.949 billion...
No Data
No Data